# Vericel Corp (VCEL) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/VCEL
## Company Profile
- Ticker: VCEL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 44.73 USD
- Market cap: 1759300454.6000001 USD
- Last updated: 2026-08-12
## Business Overview
### Advanced Therapies for Sports Medicine and Burns
Vericel is a commercial-stage advanced therapies company serving the sports medicine and severe burn care markets. Its portfolio combines cell therapies and specialty biologics aimed at repairing injuries and restoring function.
### MACI-Led Sports Medicine Franchise
MACI is Vericel's largest product and core growth driver. It is an autologous cellularized scaffold product used to repair symptomatic full-thickness cartilage defects of the knee in adults. Second-quarter 2026 MACI revenue grew 23%, supported by double-digit biopsy and implant growth and record second-quarter surgeon and procedure metrics.
### Severe Burn Care Portfolio
Vericel's burn care business includes Epicel, a permanent skin replacement for severe burns, and NexoBrid, a biologic used for eschar removal in deep partial-thickness and full-thickness thermal burns. The burn care franchise grew 22% in the second quarter, with NexoBrid posting record quarterly revenue.
### Strategic Position
Vericel is best understood as a profitable, commercial advanced-therapy company with two focused procedural franchises. Its differentiation comes from specialized biologic products, surgeon adoption, manufacturing scale, and clinical use in high-need repair settings.
## Why The Stock Is Moving

As of Aug 12, 2026, VCEL closed up 0.86% at $44.73. No new same-company headline was identified in the current news window.

## Future Catalysts

- MACI marketing authorization review in the United Kingdom.

## Recent News
- 2026-07-30 11:55 EST — [Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program](https://biopharmsignal.com/news/VCEL/vericel-reports-second-quarter-2026-financial-results-raises-full-year-financial-6a014b54) — Source: Vericel Corp
- 2026-07-16 12:30 EST — [Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026](https://biopharmsignal.com/news/VCEL/vericel-to-report-second-quarter-2026-financial-results-on-july-30-2026-99cb171e) — Source: Vericel Corp
- 2026-06-09 12:30 EST — [Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026](https://biopharmsignal.com/news/VCEL/vericel-to-present-at-the-2026-truist-securities-medtech-conference-on-tuesday-j-4259fa3f) — Source: Vericel Corp
- 2026-05-07 11:45 EST — [Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance](https://biopharmsignal.com/news/VCEL/vericel-reports-first-quarter-2026-financial-results-and-raises-full-year-financ-80a8b132) — Source: Vericel Corp
- 2026-04-23 12:30 EST — [Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026](https://biopharmsignal.com/news/VCEL/vericel-to-report-first-quarter-2026-financial-results-on-may-7-2026-fb241894) — Source: Vericel Corp